...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Advanced Biomedical Research >A comparison between standard triple therapy and sequential therapy on eradication of Helicobacter pylori in uremic patients: A randomized clinical trial
【24h】

A comparison between standard triple therapy and sequential therapy on eradication of Helicobacter pylori in uremic patients: A randomized clinical trial

机译：标准三联疗法和序贯疗法在尿毒症患者中根除幽门螺杆菌的比较：一项随机临床试验

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: The prevalence of peptic ulcer disease in hemodialysis dependent patients is higher than the general population. These patients are also more prone to upper gastrointestinal bleeding. The aim of this study was to compare the effects of a standard triple therapy with a sequential therapy on Helicobacter pylori eradication in azotemic and hemodialysis patients. Materials and Methods: Forty nine hemodialysis and azotemic patients, na?ve to H. pylori treatment, were randomized into two groups to receive either standard triple therapy (pantoprazole 40 mg, amoxicillin 500 mg and clarithromycin 250 mg twice a day for 14 days) or a sequential therapy (pantoprazole 40 mg for 10 days, amoxicillin 500 mg twice a day for the first 5 days and clarithromycin 250 mg + tinidazole 500 mg twice a day just during the second 5 days). H. pylori eradication was evaluated by fecal H. pylori antigen assessment 8 weeks after the treatment. Results: Of 49 patients, 45 patients (21 in triple therapy group and 24 in the sequential group) completed the study. Based on intention to treat analysis, H. pylori eradication rates were 66.7% (95% confidence interval [CI]: 47.8-85.5%) in standard triple therapy group and 84% (95% CI: 69.6-98.3%) in sequential therapy group ( P = 0.34 ) . Per-protocol (PP) eradication rates were (95% CI: 76.2%. 6-89.3%) 54 and 87.5% (95% CI: 68.8-95.5%), respectively ( P = 0.32). Conclusion: According to Maastricht III consensus report, the results of our study showed that sequential therapy might be a better choice compared with the standard triple therapy in azotemic and hemodialysis patients Iran. We propose to assess the effects of shorter-duration sequential therapy (less than 10 days) for H. pylori eradication.
机译：背景：依赖血液透析的患者中消化性溃疡的患病率高于一般人群。这些患者也更容易发生上消化道出血。这项研究的目的是比较标准的三联疗法和序贯疗法对消炎和血液透析患者幽门螺杆菌根除的效果。材料和方法：49名未接受幽门螺杆菌治疗的血液透析和无氧血症患者随机分为两组，接受标准三联疗法（pan托拉唑40 mg，阿莫西林500 mg和克拉霉素250 mg，每天两次，共14天）。或序贯疗法（pan托拉唑40毫克，持续10天，阿莫西林500毫克，前5天每天两次，克拉霉素250毫克+替硝唑500毫克，每天仅次于5天）。在治疗后8周，通过粪便幽门螺杆菌抗原评估来评估幽门螺杆菌的根除。结果：在49位患者中，有45位患者（三联疗法组为21位，序贯组为24位）完成了研究。根据治疗意图分析，标准三联疗法组的幽门螺杆菌根除率为66.7％（95％置信区间[CI]：47.8-85.5％），序贯疗法为84％（95％CI：69.6-98.3％）组（P = 0.34）。按协议（PP）的根除率分别为（95％CI：76.2％。6-89.3％）54和87.5％（95％CI：68.8-95.5％）（P = 0.32）。结论：根据马斯特里赫特三世共识报告，我们的研究结果表明，与标准三联疗法相比，序贯疗法可能是更好的选择。我们建议评估幽门螺杆菌根除的短期持续治疗（少于10天）的效果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号